Vutrisiran (Amvuttra™)

Amvuttra (vutrisiran) is covered for treatment of polyneuropathy of hereditary transthyretin‑mediated amyloidosis in adults and is excluded for non–FDA‑approved uses and for patients with a history of liver transplantation. Approval (up to 12 months) requires genetic confirmation of hATTR, documented symptomatic polyneuropathy (history/clinical exam or EMG/NCV), age ≥18, prescription by or in consultation with a neurologist/geneticist/amyloidosis specialist, and dosing per label 25 mg subcutaneously every 3 months.

"Amvuttra is indicated for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults."

Sign up to see full coverage criteria, indications, and limitations.